NCEL NewcelX (NCEL) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001783036
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
3
13F, latest reported quarter
What the filings say about NCEL
Activist stakes (13D), 180 days
1 filing
Largest: 25.3% of the class
NewcelX insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for NewcelX Ltd. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 81,818 shares held after it.
- 1 other insider bought within 30 days.
- 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Samuel Olivier bought about $225.0K of NCEL on Apr 27, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 3 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.7% of the 957,530 shares held after it.
- 1 other insider bought within 30 days.
- 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CSO and Director Revel Michel bought about $150.0K of NCEL on Apr 27, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 3 funds added in the latest 13F quarter.2 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
3 funds bought in last quarter
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.3% of the float short (float per yahoo 2026-10-27) · 2.1 days to cover · settled 2026-10-15
below 85% of Pharma & Biotech
The situation: each line is one rule over one dataset
League Jinn Sarl disclosed a 5%+ stake (25.3%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NCEL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-80.7%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NCEL: institutional holders (13F)
13F holdings, latest reported quarter
$2.5K
11,199 sh
$40
$11
Congress trades in NCEL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
League Jinn Sarl
Activist 13D · 2026-05-04
25.3%
Julien Ruggieri
Activist 13D · 2026-05-04
25.3%
NCEL planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 3 funds added last quarter. Each figure is a federal filing, dated the day it went public.
NCEL financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM NCEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM NCEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM NCEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Single quarter
Debt to equity
0.05x
long-term 2021-06-30 plus current 2025-12-31; equity 2025-12-31
Debt to equity NCEL
| FY Dec 2025 | 0.05x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 1.35x |
| FY Dec 2021 | 0.28x |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt NCEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on equity NCEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on assets NCEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital NCEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed NCEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing NCEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$10.4M
market value at close 2026-10-26 on 2025-12-31 shares, plus long-term 2021-06-30 plus current 2025-12-31, minus cash 2025-12-31
Enterprise value NCEL
| FY Dec 2025 | $7.3M |
| FY Dec 2024 | $73.7M |
| FY Dec 2023 | $8.4B |
| FY Dec 2022 | $16.7B |
| FY Dec 2021 | $7.2B |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield NCEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing NCEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$2.6M | -$2.1M | -$3.0M | -$15.5M |
| Net income | -$8.3M | -$7.2M | -$3.3M | -$16.5M |
| EPS (diluted) | 2.16 | 2.43 | 1.13 | -33.52 |
| Operating cash flow | -$2.8M | -$1.1M | -$3.4M | -$13.9M |
| Cash | $2.2M | $650.0K | $1.1M | $8.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
NCEL Stock Sonar score 2/7 axes
Find similar shapesCompare2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NCEL filings, in plain words
Read the full summary
1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 25.3% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
